InvestorsHub Logo

nofanofthis

09/18/13 10:06 AM

#14246 RE: KCSVEN #14245


What worries me is that although Epanova is late to the party and perhaps an inferior product, they might be able to pass Vascepa in sales simply because they have a superior company (Sales Reps) and other resources to market their product. I don't mind waiting until after Dec 20th, but shortly there after, VASCEPA needs to be in the hands of a reputable BIG PHARM. Otherwise, we could be sitting sub $10.00 for a very long time. Perhaps forever.....

grbnitz4002

09/18/13 10:10 AM

#14248 RE: KCSVEN #14245

Isn't Epanova but a branded generic of Lovasa? If Epanova is a competitor of V where is their adcomm when is NCE? What effect does Epanova have on LDL?

Biobillionair

09/18/13 12:36 PM

#14260 RE: KCSVEN #14245

Epanova is not an Anchor competitor. Epanova will never happen if '281 materializes.

'281 is very likely to happen. Affidavits signed 8-8, forwarded to examiner 9-10, track one (priority filed in August also) Hopefully NOA before December.